MedTrace Logo

Clinical Study on Optimised Removal of Protein-bound Uremic Toxins With Convective Dialysis Treatment.

NCT00337831 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2011-06-30

No results posted yet for this study

Summary

Patients will be treated with hemodiafiltration (HDF) in postdilution mode, as a control therapy, during 9 weeks. During week 5 the 1st intervention treatment, predilution hemofiltration (HF) or predilution HDF, will be performed as a midweek session. After 4 additional weeks of control therapy the other intervention treatment will be performed. Samples will be taken during week 4, 5 and 9: from inlet blood flow (0, 30, 60, 120 and 240 min), from outlet blood flow and dialysate outflow (30, 60, 120 and 240 min).

Conditions

  • Chronic Renal Failure

Interventions

PROCEDURE

Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration

Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.

Sponsors & Collaborators

  • Gambro Corporate Research, Sweden

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Raymond Vanholder, MD, PhD · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-02-28
Completion
2007-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00337831 on ClinicalTrials.gov